Scarica l'app Stockscreener
119.80
0.66%
-0.80
Dopo l'orario di chiusura:
119.48
-0.32
-0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$120.60
Aprire:
$123.99
Volume 24 ore:
1.76M
Relative Volume:
1.02
Capitalizzazione di mercato:
$23.93B
Reddito:
$5.36B
Utile/perdita netta:
$1.43B
Rapporto P/E:
16.94
EPS:
7.0718
Flusso di cassa netto:
$1.42B
1 W Prestazione:
-5.74%
1M Prestazione:
+2.52%
6M Prestazione:
+16.58%
1 anno Prestazione:
+54.13%
Intervallo 1D:
$119.52
$124.57
Intervallo di 1 settimana:
$117.00
$126.50
Portata 52W:
$76.45
$132.60
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
119.80 | 23.75B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
484.83 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
768.58 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
867.94 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
197.30 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
327.53 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-02-05 | Iniziato | H.C. Wainwright | Buy |
| 2026-01-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options - Benzinga
James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition - Benzinga
Incyte Q2 Earnings Call Highlights - Yahoo Finance
INCY Looks 18.3% Overvalued on GF Value™ as Growth Momentum Rema - GuruFocus
Earnings call transcript: Incyte Q2 2026 beats forecasts, lifts guidance - Investing.com
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript - AlphaStreet
Incyte lifts annual revenue forecast after settlement with CMS - Yahoo Finance
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte Q2 Results: Adj. EPS $3.09 Beats Estimate, Sales Rise 37% - scanx.trade
INCY Looks 18.4% Overvalued on GF Value™ as of July 28, 2026 - GuruFocus
Incyte (INCY) Q2 Earnings and Revenues Top Estimates - Yahoo Finance Australia
INCY Looks 18.4% Overvalued on GF Value™ - GuruFocus
INCY Looks 18.4% Overvalued on GF Value™ as Growth Outlook Stren - GuruFocus
Is Incyte Corp (INCY) Worth the Current Valuation After Q2 Earni - GuruFocus
Incyte beats Q2 estimates but stock dips slightly on lowered guidance By Investing.com - Investing.com South Africa
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly - Yahoo Finance
Incyte earnings beat by $1.10, revenue topped estimates - Investing.com
Incyte: Q2 Earnings Snapshot - 10TV
Incyte Revenue Rises 38 Percent to $1.67 Billion in Q2 - Quiver Quantitative
Incyte posts Q2 2026 revenue $1.67B, net income $586M; raises 2026 net sales outlook - TradingView
Incyte (NASDAQ: INCY) lifts 2026 sales outlook after strong Q2 results - Stock Titan
INCY|Incyte Corp|Price:118.880|Chg%:+1.210 - TradingKey
Form 4 Incyte Corporation For: 27 July By Investing.com - Investing.com South Africa
Incyte EVP Michael Morrissey Awarded Stock Options and Performance Shares in Equity Compensation Plan - Kalkine Media
Incyte Grants Heeson Lee Stock Options and Performance Shares Worth Notable Equity Compensation - Kalkine Media
Incyte (NASDAQ: INCY) awards EVP stock options, 8,999 performance shares - Stock Titan
Incyte Corp (INCY) awards options and performance shares to EVP - Stock Titan
INCY Looks 18.8% Overvalued on GF Value™ Heading into Q2 Earnings - GuruFocus
Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incyte Corp (INCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Incyte Corporation stock hits 52-week high at 119.6 USD By Investing.com - Investing.com South Africa
Incyte Corporation stock hits 52-week high at 119.6 USD - Investing.com
Incyte earnings on deck: Can pipeline ease Jakafi concerns? By Investing.com - Investing.com South Africa
Incyte earnings on deck: Can pipeline ease Jakafi concerns? - Investing.com
INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings - ChartMill
What To Expect From Incyte’s (INCY) Q2 Earnings - Yahoo Finance
Incyte Corp (INCY) Balance Sheet - TradingKey
The week in pharma: action, reaction and insight – week to July 24, 2026 - The Pharma Letter
Incyte Corp (INCY) Income Statement - TradingKey
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner? - Yahoo Finance
Incyte stock trades steady as Jakafi revenue supports 2024 outlook - AD HOC NEWS
INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup - ChartMill
INCY Maintained by JP Morgan -- Price Target Raised to $110 - GuruFocus
Incyte Corp (INCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
INCY Maintained by Morgan Stanley -- Price Target Raised to $104 - GuruFocus
Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Incyte stock trades steadily as Jakafi revenue supports oncology pipeline - AD HOC NEWS
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine? - Yahoo Finance
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):